Tela Bio (TELA): Stonepine Capital Management, LLC cut its TELA stake below 5% (0%) 0.0%
Stonepine Capital Management, LLC cut its TELA stake below 5% (0%).
- 0.0%
- Stake
- Stake as of
- Sep 30, 2026
- Filed
- Nov 16, 2026
What stands out in this filing
- Reported stake 0.0%.
- The filing reports the stake below 5%, the level at which these reports stop being required.
- A 13G is the short form for a passive owner of more than 5%.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 3, 2026, the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”) determined that, Antony Koblish will no longer serve as the Company’s Chief Executive Officer and the principal executive officer, effective on August 3, 2026 (the “ Effective Date ”).”
- Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 7, 2026 (the “ Effective Date ”), the Company and Mr. Koblish entered into a Separation Agreement and General Release (the “ Separation Agreement ”).”
- Aug 10, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 14, 2026Insider · 14 days before an 8-KCEO purchased ~$10K of TELA shares in the open market
- Aug 17, 2026Insider · 11 days before an 8-KCEO purchased ~$8.3K of TELA shares in the open market
- Aug 28, 2026Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“Effective on August 31, 2026, Roberto Cuca stepped down from his position as the Company’s Chief Financial Officer, Chief Operating Officer, Corporate Secretary and principal financial officer.”
- Sep 14, 2026Insider · 1 day before an 8-KDirector purchased ~$26K of TELA shares in the open market
- Sep 15, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market, as the minimum bid price of the Company’s common…”
- Sep 15, 2026InsiderDirector purchased ~$53K of TELA shares in the open market
- Sep 16, 2026InsiderDirector purchased ~$58K of TELA shares in the open market
- Sep 17, 2026InsiderDirector purchased ~$31K of TELA shares in the open market
- Sep 28, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
- Sep 28, 2026FDAFDA device clearance: Liora Monofilament Scaffold
What came next
- Nov 10, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 13, 20265% stakeNorth Run Capital, LP reported a passive stake (13G) of 7.8%
- Nov 13, 20265% stakeNantahala Capital Management, LLC reported a passive stake (13G) of 14.5%
- Nov 16, 20265% stakeStonepine Capital Management, LLC reported a passive stake (13G)
How to read SEC Schedule 13G
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Tela Bio
For Tela Bio, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TELA page.
How this filing works
Explore the data
Common questions
What does this filing report about Tela Bio (TELA) stock?
Stonepine Capital Management, LLC cut its TELA stake below 5% (0%). Of the company, Schedule 13G (passive).
When did it happen, and when was it made public?
Stake as of: Sep 30, 2026. Filed: Nov 16, 2026.
What stands out in this filing?
Reported stake 0.0%. The filing reports the stake below 5%, the level at which these reports stop being required. A 13G is the short form for a passive owner of more than 5%.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Tela Bio recently?
For Tela Bio, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the TELA page.
Does this mean TELA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Tela Bio
- SEC Form 4Sep 19, 2026
- SEC Form 4Sep 19, 2026
- SEC Form 4Sep 17, 2026
- SEC Form 4Sep 17, 2026
- SEC Form 4Aug 20, 2026
- SEC Form 4Aug 18, 2026
Everything OQRO holds on this company is on its TELA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data